anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A multicenter, double-blind, placebo-controlled, randomized, four week study was conducted in patients with a diagnosis of symptomatic non-erosive GERD made primarily by presentation of symptoms. These patients who identified heartburn as their primary symptom, had a history of heartburn for six months or longer, had heartburn on at least four of seven days immediately prior to randomization and had no esophageal erosions as confirmed by endoscopy. However, patients with symptoms which were not acid-related may not have been excluded using these inclusion criteria. Patients were randomized to one of the following treatment groups: dexlansoprazole delayed-release capsules 30 mg daily, 60 mg daily, or placebo. A total of 947 patients were enrolled and ranged in age from 18 to 86 years (median age 48 years) with 71% female. Race was distributed as follows: 82% Caucasian, 14% Black and 4% Other.

Dexlansoprazole delayed-release capsules 30 mg provided statistically significantly greater percent of days with heartburn-free 24 hour periods over placebo as assessed by daily diary over four weeks (see Table 11). Dexlansoprazole delayed-release capsules 60 mg once daily was studied and provided no additional clinical benefit over dexlansoprazole delayed-release capsules 30 mg once daily.

* Statistically significant vs placebo

A higher percentage of patients on dexlansoprazole delayed-release capsules 30 mg had heartburn-free 24 hour periods compared to placebo as early as the first three days of treatment and this was sustained throughout the treatment period (percentage of patients on Day 3: dexlansoprazole delayed-release capsules 38% vs placebo 15%; on Day 28: dexlansoprazole delayed-release capsules 63% vs placebo 40%).
BACKGROUND: Icariin (ICA) inhibits inflammatory response in various diseases, but the mechanism underlying ICA treating airway inflammation in asthma needs further understood. We aimed to predict and validate the potential targets of ICA against asthma-associated airway inflammation using network pharmacology and experiments.
METHODS: The ovalbumin-induced asthma-associated airway inflammation mice model was established. The effects of ICA were evaluated by behavioral, airway hyperresponsiveness, lung pathological changes, inflammatory cell and cytokines counts. Next, the corresponding targets of ICA were mined via the SEA, CTD, HERB, PharmMapper, Symmap database and the literature. Pubmed-Gene and GeneCards databases were used to screen asthma and airway inflammation-related targets. The overlapping targets were used to build an interaction network, analyze gene ontology and enrich pathways. Subsequently, flow cytometry, quantitative real-time PCR and western blotting were employed for validation.
RESULTS: ICA alleviated the airway inflammation of asthma; 402 targets of ICA, 5136 targets of asthma and 4531 targets of airway inflammation were screened; 216 overlapping targets were matched and predicted ICA possesses the potential to modulate asthmatic airway inflammation by macrophage activation/polarization. Additionally, ICA decreased M1 but elevated M2. Potential targets that were disrupted by asthma inflammation were restored by ICA treatment.
CONCLUSIONS: ICA alleviates airway inflammation in asthma by inhibiting the M1 polarization of alveolar macrophages, which is related to metabolic reprogramming. Jun, Jak2, Syk, Tnf, Aldh2, Aldh9a1, Nos1, Nos2 and Nos3 represent potential targets of therapeutic intervention. The present study enhances understanding of the anti-airway inflammation effects of ICA, especially in asthma.
The invention discloses a full-automatic segmentation method for kidney tumors, which comprises an experimental environment and an algorithm research part. The experimental platform is a Windows10 operating system, and the display card is NVIDIA GeForce GTX 1080 Ti. The algorithm research mainly comprises the rough segmentation of the kidney of the CT image and the fine segmentation of the tumor of the kidney. The operation flow of the whole system is as follows: 1. the Windows10 operating system is installed with the configuration of Anaconda version of Anaconda3, python version of 3.6, CUDA version of 10.0, PyTorch version of 1.6, and other required installation packages. 2. The data set is subjected to a preprocessing operation that runs in pycharm, which houses the Anaconda environment. 3. The processed data set is segmented using RAUNet. 4. And carrying out post-processing on the pictures output after training. 5. The model is evaluated on the test set by the evaluation index. The invention mainly aims to promote the development of intelligent medical treatment, save labor cost, improve segmentation precision and prevent diseases in advance, thereby ensuring human health.
Patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
A pharmaceutical order processing system, components thereof, and associated methods for filling a prescription order. The pharmaceutical order processing system includes a lower insert placer, a syringe placer, a dosing cup placer, a pharmaceutical container placer, and/or an upper insert placer. The lower insert placer places a lower insert into a box. The syringe placer places a syringe into a syringe compartment of the lower insert. The dosing cup placer places a dosing cup into a dosing cup compartment of the lower insert. The pharmaceutical container placer places a pharmaceutical container into a pharmaceutical container compartment of the lower insert. The upper insert placer places an upper insert into the box after the box has received the lower insert and the lower insert has received the syringe, the dosing cup and the pharmaceutical container.
This single-arm, single-center, open-label trial enrolls patients with limited and surgically resectable peritoneal metastases from colorectal cancer, no distant metastases, and no contraindication to major surgery. After signature of informed consent, patients undergo a preliminary laparoscopy to confirm diagnosis of peritoneal metastases, stage the disease, and obtain representative samples of peritoneal metastases. The investigators will use patient-derived organoids to select tailored hyperthermic intra-peritoneal chemotherapy (HIPEC) regimens in an in vitro model HIPEC. A set of candidate drugs suitable for intraperitoneal administration are tested on tumor-derived organoids under the same conditions as in the clinical practice (same drug combinations, concentration, exposure time, temperature). Different concentrations are tested to generate reproducible dose-response curves. Patients receive 3-6 month preoperative systemic chemotherapy with targeted agents, according to current guidelines. Those not experiencing disease progression during preoperative systemic chemotherapy will have cytoreductive surgery and HIPEC with drugs selected on the organoid-based preclinical model. Patients will undergo postoperative follow-up.
The present invention relates to an eco-friendly liquid pouch packaging apparatus and a configuration method thereof. According to the present invention, eco-friendly liquid pouches, which is made of various liquid contents such as a shampoo, a conditioner, a toothpaste, and a disinfectant contained in a gel-type membrane, are packaged according to a purpose of travel, business trip, place of use, etc. In addition, a user can take out and use the eco-friendly liquid pouch one by one when desired. Therefore, convenient and environmentally friendly usage is possible while generation of a garbage is blocked. In addition, there is no fear of leakage of a content due to a container problem. In addition, a volume is reduced, so luggage can be reduced when the travel or the business trip. The eco-friendly liquid pouch packaging apparatus of the present invention comprises: a packaging main body; and a discharging unit.
PURPOSE: To obtain the subject non-irritant and non-metal-corrosive resin oil by extraction, from HINOKI (Chamaecyparis Spach) as an evergreen shrub by removing tar and acidic components, and to obtain a wound curative agent and epithelialization promoter each containing this resin oil. CONSTITUTION: This aromatic neutral resin oil is obtained by extracting the trunks, leaves, wood chips, etc., of evergreen shrubs of Thujopsis dolabrata Sieb. et Zucc (ASUNARO) or Chamaecyparis Spach (HINOKI) family as a raw material through steam distillation. To remove tar component and acidic component such as thujaplicin, an alkali solution (e.g. of NaOH) is added to the extraction system followed by heating and agitation. This resin oil which is non-irritant and noncorrosive to metals has body temperature holding and humectant effect and blood circulation-improving action, has wound-curative and epithelialization promotive action as well as antibacterial and miteproofing effect.
Virologically suppressed HIV positive participants, on a stable antiretroviral regimen, who switched to the 2-Drug Regimen JULUCA (Dolutegravir \[DTG\] / Rilpivirine \[RPV\]) were included in the study. Participants were followed-up for approximately 3 years during routine clinical practice.
In a previous study of candidate HIV vaccines, the evidence suggested that administration of a booster vaccination with a different vaccine preparation may produce a better immune response than administration of HIVAC-1e vaccine alone.

Seventy healthy volunteers are randomized to one of four groups. Groups A and D receive one initial immunization with HIVAC-1e followed by two boosts with subunit gp120 and Env 2-3, respectively, at months 8 and 12. Group B receives two immunizations with HIVAC-1e at months 0 and 8 followed by a single boost with subunit gp120 at month 12. Group C receives three doses of subunit gp120 only at months 0, 8 and 12. (Per 10/01/92 amendment, boosts with VaxSyn (gp160) have been eliminated.) Subjects are followed for 18 months.
Participants received 30-minute sessions of strategy and self-monitoring practice within the context of everyday activities. These sessions were delivered either daily or twice a day. The total number of sessions varied depending on the participant's length of stay in acute rehabilitation.
Sulindac, and its sulfone and sulfide metabolites, are 93.1, 95.4, and 97.9% bound to plasma proteins, predominantly to albumin. Plasma protein binding measured over a concentration range (0.5-2.0 µg/mL) was constant. Following an oral, radiolabeled dose of sulindac in rats, concentrations of radiolabel in red blood cells were about 10% of those in plasma. Sulindac penetrates the blood-brain and placental barriers. Concentrations in brain did not exceed 4% of those in plasma. Plasma concentrations in the placenta and in the fetus were less than 25% and 5% respectively, of systemic plasma concentrations. Sulindac is excreted in rat milk; concentrations in milk were 10 to 20% of those levels in plasma. It is not known if sulindac is excreted in human milk.
A: 5 drops of Chymosin is added to ½ a liter of milk. This is to be consumed during breakfast.
PURPOSE: A composition containing Gleditsia sinensis extract is provided to prevent hyperglycermia without side effects. CONSTITUTION: A pharmaceutical composition for preventing or treating diabetes or complication contains Gleditsia sinensis extract as an active ingredient. A pharmaceutical composition for suppressing alpha-glucosidase contains the Gleditsia sinensis extract as an active ingredient. The extract is prepared using methanol or ethanol. A method or suppressing alpha-glucosidase activity in a sample comprises a step of contacting the Gleditsia sinensis extract with the sample. A neutraceutical composition for preventing or treating diabetes and complication contains the Gleditsia sinensis extract.
Total gastrectomy with D2 lymphadenectomy will be performed with curative treated intent. The type of reconstruction will be with jejunal interposition reconstruction.
S-palmitoylation is a protein post-translational modification involving the attachment of a palmitic acid molecule to cysteine residues. This modification influences protein trafficking toward cellular membranes and is finely regulated by a class of enzymes named zinc finger DHHC domain containing (zDHHC) S-acyltransferases. Proteins critically involved in Alzheimer's disease (AD), such as APP and BACE1, are targets of S-palmitoylation. Higher levels of S-palmitoylated proteins have been found in both post-mortem brain samples and brain organoids derived from induced pluripotent stem cells (hiPSCs) obtained from AD patients. Notably, both neurons and brain organoids derived from human AD hiPSCs exhibited molecular, morphological, and functional alterations reminiscent of AD. Intranasal administration of the palmitoylation inhibitor 2-bromopalmitate (2-BP) significantly counteracted LTP and memory deficits in 3×Tg-AD mice, extended lifespan, and decreased Aß deposition. Higher levels of zDHHC7 and zDHHC21 were also found in the hippocampus of 3×Tg-AD mice. Silencing of zDHHC7 in the hippocampus of 3×Tg-AD mice prevented cognitive deficits and Aß accumulation, along with counteracting palmitoylation of proteins critically involved in neuronal function. This confirms that modulation of zDHHC activity may be exploited for AD treatment.

The idea underlying this project is based on the assumption that zDHHC enzymes and alteration of protein S-palmitoylation play a key role in the onset and progression of AD. Dysregulated zDHHC activity and aberrant S-palmitoylation of neuronal proteins critically involved in the regulation of brain plasticity, neuroinflammation, and Aß metabolism can affect synaptic function, protein homeostasis, and mitochondrial activity, leading to the development of neurodegeneration and cognitive deficits. A druggable target, zDHHC7, has been identified to test the efficacy of novel therapeutic approaches. This study aims to validate a new strategy targeting zDHHC enzymes in human experimental models of AD. Human models will allow an understanding of the translation potential of these approaches to human disease, to be validated in subsequent clinical trials whose implementation exceeds the duration of the present project.
The population of the study consisted of urinary catheterized patients treated in the clinics of a Training and Research Hospital. G\*Power power analysis was used to calculate the number of individuals constituting the sample. The effect size was set to 0.80, which is a high level according to Cohen for comparing the means of independent samples. To ensure that the statistical power of the study was above 95%, the sample size was set at a 5% significance level and the effect size was 0.5. (df = 68; t = 1.668) The sample size was calculated as 70 patients. The study is planned to be conducted with 35 patients for each of the two study groups.
FIELD: medicine. SUBSTANCE: preparation is obtained from bee bread with addition of different components. Product is dried in vacuum chamber with heating and extraction of bee bread. Raw material is preliminarily dried (prior to drying in vacuum chamber) to humidity of 10-12% by convective method. Then raw material is decontaminated, cooled, and bee bread is extracted at temperature of 0-5 C. In vacuum chamber product is dried to humidity not exceeding 1%. In this case, rarefaction is increased successively from 100 to 1 mm Hg. Product is crushed till powder is obtained. Installation of method embodiment has airtight chamber 1 with air ducts 2 and 3, fans 4, electric heaters 5, refrigerating chamber 6 with air ozonizer 7 and separator-crusher 9, and vacuum chamber 10 provided with infrared thermal radiator 11 and system 12 for cooling external surface of chamber 10. Installation also includes vacuum pumps 13, 14, granule mixer 15 and micromill 16. EFFECT: higher efficiency and economy of process. 9 cl, 1 dwg
MDGN-002 will be supplied in vials of 150 mg/mL. MDGN-002 will be administered by SQ injection in the abdomen every 14 days at 1 of 2 dose levels: 1.0 mg/kg or 3.0 mg/kg.
This cohort includes patients aged 65 and older admitted with acute respiratory symptoms who undergo lung ultrasound (LUS) upon hospital admission. LUS findings in this cohort show significant abnormalities such as pleural effusions, consolidations, or diffuse comet-tail artifacts (B-lines). The primary interest is to assess the presence of LUS abnormalities and their correlation with clinical outcomes, including delirium, duration of hospitalization, need for oxygen therapy, non-invasive ventilation, and mortality.
The ultimate goal is for participants to complete approximately 130-180 minutes/week of aerobic training, at 60% to 75 % of the individually determined exercise capacity (VO2peak), for 16 weeks. VO2peak will be determined by the second CPET performed at baseline.
BACKGROUND: Globally, non-communicable diseases (NCDs) are increasingly the primary cause of mortality and morbidity among women. Like many developing countries, Bangladesh also faces a growing burden of NCDs. The "Multisectoral Action Plan for Prevention and Control of Non-communicable Diseases, 2018-2025" signifies Bangladesh's commitment to comprehensively combating the rising burden of NCDs. This study investigates the perceptions of those involved in developing the action plan and if/how a gender lens was incorporated into its implementation.
METHODS: In-depth interviews were conducted with 25 key individuals involved in a high-level committee to develop and implement Bangladesh's multisectoral action plan to address the burden of NCDs. Data were collected between July and November 2021, and thematic analysis was conducted.
RESULTS: The findings revealed that interviewees believed the multisectoral action plan adopted a population-wide approach without considering gender-specific needs. This study presents the explanations for this inattention under five themes: (1) A population-level approach to NCD prevention; (2) Understanding women's health beyond reproductive health; (3) Absence of gender-specific programs; (4) Lack of consideration of gender constraints on physical activity; and (5) Lack of collaborative efforts to address NCDs beyond the health ministry.
CONCLUSION: In conclusion, governments in countries like Bangladesh can develop more effective strategies to reduce the disease burden of NCDs among women by recognizing and addressing the gendered nature of preventive health. This can be achieved by promoting gender-responsive research, programs, and policy initiatives that consider women's specific health concerns, ultimately leading to better health outcomes for all.
The collection of microbes inhabiting the human gastrointestinal (GI) tract, known as the gut microbiota, is increasingly recognized as a mediator of GI, immunologic, and neuropsychologic responses to various environmental and physiologic stressors. The hypobaric hypoxia characteristic of high altitude environments is a stressor that has recently been associated with increased GI permeability, and which has been shown to cause decrements in immune, neuropsychological and physical function. To what extent modulation of the human gut microbiota can mitigate these responses during high altitude exposure is undetermined. The aim of this randomized, crossover clinical trial is to determine the efficacy of a gut microbiota-targeted nutritional intervention containing a blend of fermentable fibers and polyphenols (FP) for mitigating increases in GI permeability, and decrements in immune function and neuropsychologic performance following rapid ascent to simulated high altitude. Fifteen healthy young adults will participate in each of three study phases in random order. Each phase will include a 14-day supplementation period in which participants will consume 1 of 2 supplement bars: placebo (PL, will be consumed during 2 phases) and FP supplementation (will be consumed during one phase only). During the final 2-d of each phase, participants will live in a hypobaric chamber. During one phase the chamber environment will mimic low-altitude conditions (SHAM). During two phases the chamber environment will mimic the barometric pressure at Pike's Peak CO (460 mmHg; HA).
BACKGROUND: Plasma circulating tumor DNA (ctDNA) is a promising biomarker for metastatic colorectal cancer (mCRC); however, its role in characterizing recurrence sites after mCRC resection remains poorly understood. This single-institution study investigated the timing of ctDNA detection and its levels in the context of recurrence at different sites after mCRC resection.
STUDY DESIGN: Patients who underwent optimal resection of CRC metastases involving the peritoneum, distant lymph nodes, or liver, with serial postoperative tumor-informed ctDNA assessments (Signatera) were included. Recurrence sites, as defined by surveillance imaging or laparoscopy, were categorized as peritoneal-only and other distant sites (liver, lung, lymph nodes, or body wall).
RESULTS: Among the 31 included patients, ctDNA was detected in all 26 (83.4%) patients with postoperative recurrence and was persistently undetectable in 5 patients who did not experience recurrence. At 3 months postsurgery, ctDNA was detected in 2 (25%) of 8 patients with peritoneal-only recurrence and 17 (94.4%) of 18 patients with distant recurrence (p < 0.001). Beyond 3 months, ctDNA was detected in the remaining 6 patients with peritoneal-only disease and 1 patient with distant disease. ctDNA detection preceded the clinical diagnosis of recurrence by a median of 9 weeks in both groups. At recurrence, peritoneal-only recurrent cases exhibited lower ctDNA levels (median 0.4 mean tumor molecules/mL, interquartile range 0.1 to 0.8) compared with distant recurrence (median 5.5 mean tumor molecules/mL, interquartile range 0.8 to 33.3, p = 0.004).
CONCLUSIONS: Peritoneal-only recurrence was associated with delayed ctDNA detection and low levels of ctDNA after optimal resection for mCRC. ctDNA testing may effectively characterize recurrence sites and may help guide subsequent treatments specific to the disease sites involved.
Propolis is a resinous product collected by bees from various types of plants, which contains a number of compounds with biological activity, including antibacterial, antioxidant and anti-inflammatory activity. These properties make propolis an ideal candidate for use as a functional ingredient in food. Raw propolis is dissolved in ethyl alcohol with a concentration of at least 50% (vol.) in a ratio of 1:3 to 1:10 and applied to a suitable carrier, preferably an extruded material of plant origin. The mixture is then dried at a temperature of 60°C. The material obtained in this way can be ground and used, for example, in capsules as a nutritional supplement, or separately, for example, in yogurt and cereals.
A 57-year-old male with a background of chronic pancreatitis presented with acutely worsening abdominal pain and vomiting. He previously had a pancreatic duct stent in situ which had been removed 1 year prior to presentation. Initially suspected to be acute-on-chronic pancreatitis, a computed tomography (CT) scan of the abdomen and pelvis revealed an atrophic pancreas and a new mass in the pancreatic head, raising the suspicion of pancreatic malignancy. An urgent endoscopic ultrasound (EUS)-guided fine needle biopsy of the pancreatic head mass surprisingly revealed the presence of actinomyces colonies on histological evaluation. Prompt initiation of a prolonged antibiotic course led to significant clinical and radiological improvement. This case highlights the rare presentation of pancreatic actinomycosis which can often masquerade as malignancy. Although a gut commensal, actinomyces can elicit pathogenic effects if allowed to enter tissues through a breach in the mucosal lining such as following abdominal surgery or pancreatic duct intervention as observed in this case. Early recognition and appropriate treatment with antibiotics can lead to clinical recovery and complete resolution of the infection.